- Home
- USEA vs LYRA Comparison
USEA vs LYRA Comparison
Compare USEA & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USEA
- LYRA
- Stock Information
- Founded
- USEA 2004
- LYRA 2005
- Country
- USEA Greece
- LYRA United States
- Employees
- USEA N/A
- LYRA N/A
- Industry
- USEA Marine Transportation
- LYRA Medical/Dental Instruments
- Sector
- USEA Consumer Discretionary
- LYRA Health Care
- Exchange
- USEA Nasdaq
- LYRA Nasdaq
- Market Cap
- USEA 10.5M
- LYRA 11.6M
- IPO Year
- USEA N/A
- LYRA 2020
- Fundamental
- Price
- USEA $1.58
- LYRA $7.47
- Analyst Decision
- USEA
- LYRA Hold
- Analyst Count
- USEA 0
- LYRA 1
- Target Price
- USEA N/A
- LYRA $16.00
- AVG Volume (30 Days)
- USEA 21.3K
- LYRA 21.5K
- Earning Date
- USEA 08-06-2025
- LYRA 08-12-2025
- Dividend Yield
- USEA 2.63%
- LYRA N/A
- EPS Growth
- USEA N/A
- LYRA N/A
- EPS
- USEA N/A
- LYRA N/A
- Revenue
- USEA $42,625,000.00
- LYRA $770,000.00
- Revenue This Year
- USEA N/A
- LYRA N/A
- Revenue Next Year
- USEA $11.62
- LYRA $139.18
- P/E Ratio
- USEA N/A
- LYRA N/A
- Revenue Growth
- USEA N/A
- LYRA N/A
- 52 Week Low
- USEA $1.00
- LYRA $3.81
- 52 Week High
- USEA $2.78
- LYRA $37.50
- Technical
- Relative Strength Index (RSI)
- USEA 51.76
- LYRA 48.46
- Support Level
- USEA $1.50
- LYRA $6.92
- Resistance Level
- USEA $1.57
- LYRA $7.57
- Average True Range (ATR)
- USEA 0.07
- LYRA 0.46
- MACD
- USEA -0.01
- LYRA 0.18
- Stochastic Oscillator
- USEA 34.09
- LYRA 90.57
About USEA United Maritime Corporation
United Maritime Corp operates as a shipping company currently specializing in the seaborne transportation of dry bulk commodities. It currently operates one LR2 tanker vessel and three Capesize dry bulk vessels, two Kamsarmax dry bulk vessels, and three Panamax dry bulk vessels, with an aggregate cargo-carrying capacity of approximately 1,004,289 dwt.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.